The worldwide prevalence of type 2 diabetes is rising dramatically, leading to an increase in the complications of this disease. The total number of people with diabetes may reach 440 million worldwide by
structural formula of saxagliptin in shown in Figure 1 . It has a low K(i) of 3.6nM for DPP-4 in vitro. 15 The formation of the covalent enzymeinhibitor complex is reversible and dissociates with a k off of (5.5+0.4) x 10 -5 s -1 . 16 Saxagliptin also demonstrated potency that was more than 4,000-fold greater than DPP-4 when tested against a number of other proteases, 17 making it more potent than sitagliptin or vildagliptin.
Regarding toxicity, no data have been published so far. Saxagliptin is partially metabolized in the liver, generating a metabolite that also inhibits DPP-4.
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Pharmacokinetics
The half maximal inhibitory concentration (IC 50 ) for DPP-4 inhibition is 30nM, and the effective dose 50 (ED 50 ) after a single dose of 0.1μmol/kg and 0.5μmol/kg is 0.5 and six hours, respectively, showing sufficient activity over time for once-daily dosing. Endogenous GLP-1 concentrations rise 1.5-to three-fold after saxagliptin administration. 17, 19 Pharmacokinetic and pharmacodynamic characteristics were investigated in healthy subjects at doses up to 400mg daily and in patients with type 2 diabetes in doses from 2.5 to 50mg once daily. A dose-dependent inhibition of DPP-4 was observed, with a maximal inhibiting effect at 150mg. DPP-4 inhibition 24 hours post-dose for 2.5mg and 400mg saxagliptin was 50 and 79% of pre-dose activity, respectively.
Doses of 400mg once-daily saxagliptin for two weeks were safe and welltolerated. 17, 18 No specific drug-drug interactions between saxagliptin and other common medications were observed.
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Clinical Studies
Phase I studies demonstrated a dose-dependent inhibition of DPP-4 in a dose range from 2.5 to 100mg once daily, as described above. Results from phase II studies are reported in references 17, 18, and 24. A phase IIb study with 10mg saxagliptin once daily generated good efficacy and tolerability data. saxagliptin and placebo, respectively).
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Saxagliptin has been extensively tested in phase III studies. Figure 2 gives an overview of the studies and number of patients involved. [25] [26] [27] [28] [29] A dose-ranging study in patients with an average HbA 1c of 7.9% (range 6.8-9.7%) at baseline with saxaglitptin doses from 2.5 to 40mg once daily showed a dose-dependent drop in HbA 1c by 0.7-0.9% (placebosubtratced HbA 1c reduction 0.45-0.63%). Fasting plasma glucose was also dose-dependently lowered. Saxaglitpin did not cause hypoglycemia, was well tolerated, and was weight-neutral. 30 One placebo-controlled, randomized, double-blind multicenter study investigated change in HbA 1c as the primary end-point in more than 400 drug-naïve type 2 diabetes patients. The baseline HbA 1c range was 7-10%, and HbA 1c was reduced by 0.7-0/9%. 26 Saxagliptin was given once daily in doses ranging from 2.5 to 10mg as a monotherapy for 24
weeks. It was generally well tolerated and demonstrated clinically meaningful reductions in key parameters of glycemic control compared with placebo (see Figure 3 ).
An initial combination therapy with saxagliptin plus metformin versus saxagliptin or metformin monotherapy lasting for 24 weeks demonstrated that saxagliptin 5mg plus metformin and saxagliptin 10mg plus metformin demonstrated statistically significant decreases in glycemic parameters. 28 The HbA 1c was lowered by an additional 0.5% by the 5mg saxagliptin dose and by 0.8% by the 10mg dose. 28 As add-on therapy to metformin, saxagliptin (2.5, 5, or 10mg once daily) or placebo plus a stable dose of metformin (1,500-2,500mg daily) also led to statistically significant improvements in glycemic parameters, and the combination was well tolerated. 29 When added to a submaximal dose of the sulfonylurea glyburide, saxagliptin also significantly improved glycemia and was superior to uptitration of the sulfonylurea. 27 Saxagliptin as add-on therapy was also investigated in combination with glitazones in 555 patients not optimally controlled with a stable dose of either pioglitazone or rosiglitazone who had a baseline HbA 1c ranging from 7.0 to 10.5%. The primary end-point was change in HbA 1c . 17, 18, 24 Saxagliptin lowered HbA 1c by 0.58-0.94% (see Figure 4) .
A study assessing the efficacy of 5mg saxagliptin daily used different insulin secretion parameters after 12 weeks as efficacy measures in 156 patients who were not well controlled with diet and exercise (HbA 1c between 6.0 and 8.0%). 17, 18, 24 A study in patients with impaired renal function (creatinine clearance <50ml/min) investigating the efficacy and safety of 2.5mg saxagliptin once daily is still ongoing. 17, 18, 24 A study in 18 patients with hepatic impairment (Child-Pugh Score A-C) compared the pharmacokinetics of 10mg saxagliptin with that of a 
Side Effects and Contraindications
Saxagliptin was tested in type 2 diabetes patients in doses up to 100mg once daily without adverse reactions and in healthy volunteers at doses up to 400mg per day. Safety data and tolerability were good. 17, 18, 24 Additionally, data from longer studies examining the safety and adverse effects of saxagliptin are available. As an add-on to metformin, saxagliptin at doses from 2.5 to 10mg once daily were well tolerated and did not have a significant rise in specific adverse reactions compared with placebo. The incidence of hypoglycemia was not increased compared with placebo. 17, 18, 24 A small study using doses of up to 40mg saxagliptin once daily in patients with type 2 diabetes did not reveal a higher incidence of specific adverse events compared with the placebo group. 30 Studies investigating possible drug-drug interactions with saxagliptin did not reveal any interaction between saxagliptin and common over-the-counter drugs, digitoxin and anticoagulants. 17, [20] [21] [22] In patients with renal or hepatic impairment, more data have to be collected to give a complete picture. In hepatic organ dysfunction, a reduction to lower doses seems to be feasible without additional side effects. Saxagliptin was well tolerated in a small study of such patients receiving a single saxagliptin dose. 31 A study in patients with renal impairment is still ongoing. to that seen with placebo. Hormonal counter-regulation at low glucose concentrations is not impaired, but actually improved. 32 Animal studies and in vitro data from isolated human islets suggest a potential for DPP-4 inhibitors to increase beta-cell function and mass, pointing to a putative beneficial effect on type 2 diabetes disease progression.
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The DPP-4 inhibitors sitagliptin and vildagliptin have been in use for a few years. 10, 11 Saxagliptin, the third compound in the class, has now been approved and has demonstrated very satisfactory data on the improvement of glycemic parameters. It has also shown a good safety profile and tolerability over a time range of up to 24 weeks in clinical studies in a large cohort of patients. 17, 18, [24] [25] [26] [27] [28] [29] [30] Compared with other DPP-4
inhibitors, saxagliptin is comparably efficacious and safe as monotherapy as well as in combination with metformin or a glitazone. 17, 18, 24, 25, 28 Further studies have demonstrated that there are no drug-drug interactions of concern with over-the-counter drugs, anticoagulants, antacids, and saxaglitpin, but no severe side effects. 31 A study on patients with renal impairment is under way. 17 In a head-to-head study, saxagliptin was non-inferior to sitagliptin. 33 A meta-analysis of the existing phase II and III studies showed favorable cardiovascular outcomes in the saxagliptin-treated patients (see Figure  5 ). 34 The development of saxagliptin and the other DPP-4 inhibitors emphasizes the advantages of DPP-4 inhibitors over classic insulin secretagogs (sulfonylureas and metiglinides) regarding their glucosedependent action without intrinsic risk of hypoglycemia and their weight neutrality. 35 n
